558 related articles for article (PubMed ID: 22869151)
1. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
2. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer.
Rizwi FA; Abubakar M; Puppala ER; Goyal A; Bhadrawamy CV; Naidu VGM; Roshan S; Tazneem B; Almalki WH; Subramaniyan V; Rawat S; Gupta G
J Environ Pathol Toxicol Oncol; 2023; 42(4):15-29. PubMed ID: 37522565
[TBL] [Abstract][Full Text] [Related]
4. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus.
Heim MH
J Recept Signal Transduct Res; 1999; 19(1-4):75-120. PubMed ID: 10071751
[TBL] [Abstract][Full Text] [Related]
5. The JAK/STAT signaling pathway: from bench to clinic.
Hu X; Li J; Fu M; Zhao X; Wang W
Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
[TBL] [Abstract][Full Text] [Related]
6. HiJAKing the epigenome in leukemia and lymphoma.
Drennan AC; Rui L
Leuk Lymphoma; 2017 Nov; 58(11):2540-2547. PubMed ID: 28402164
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
8. The PTP1B mutant PTP1B∆2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Zahn M; Kaluszniak B; Möller P; Marienfeld R
Carcinogenesis; 2021 Apr; 42(4):517-527. PubMed ID: 33382412
[TBL] [Abstract][Full Text] [Related]
9. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
[TBL] [Abstract][Full Text] [Related]
10. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Chai J; Choudhuri J; Wang Q; Fang Y; Shi Y; Kamel J; Shah N; Sica RA; Kornblum N; Konopleva M; Mantzaris I; Shastri A; Gritsman K; Verma A; Goldfinger M; Goel S; Wang Y; Tian X
Leuk Lymphoma; 2023 Oct; 64(10):1662-1672. PubMed ID: 37424335
[TBL] [Abstract][Full Text] [Related]
12. Novel therapies for myelofibrosis.
Stein BL; Cervantes F; Giles F; Harrison CN; Verstovsek S
Leuk Lymphoma; 2015; 56(10):2768-78. PubMed ID: 25860240
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
Hu M; Liu R; Li J; Zhang L; Cao J; Yue M; Zhong D; Tang R
Ann Hematol; 2023 Sep; 102(9):2445-2457. PubMed ID: 37209119
[TBL] [Abstract][Full Text] [Related]
14. Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ; Chavez SA; Estrada Jimenez VH; Sun S; Li L; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834019
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.
Groh M; Fenwarth L; Labro M; Boudry A; Fournier E; Wemeau M; Marceau-Renaut A; Daltro de Oliveira R; Abraham J; Barry M; Blanche P; Bodard Q; Braun T; Chebrek S; Decamp M; Durel CA; Forcade E; Gerfaud-Valentin M; Golfier C; Gourguechon C; Grardel N; Kosmider O; Martis N; Melboucy Belkhir S; Merabet F; Michon A; Moreau S; Morice C; Néel A; Nicolini FE; Pascal L; Pasquier F; Pieragostini A; Roche-Lestienne C; Rousselot P; Terriou L; Thiebaut-Bertrand A; Viallard JF; Preudhomme C; Kahn JE; Lefevre G; Duployez N;
Am J Hematol; 2024 Jun; 99(6):1108-1118. PubMed ID: 38563187
[TBL] [Abstract][Full Text] [Related]
16. JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages.
Hedl M; Proctor DD; Abraham C
J Immunol; 2016 Nov; 197(9):3695-3704. PubMed ID: 27664279
[TBL] [Abstract][Full Text] [Related]
17. Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies.
Suriya U; Mahalapbutr P; Geronikaki A; Kartsev V; Zubenko A; Divaeva L; Chekrisheva V; Petrou A; Oopkaew L; Somngam P; Choowongkomon K; Rungrotmongkol T
Int J Biol Macromol; 2024 Mar; 260(Pt 2):129308. PubMed ID: 38218283
[TBL] [Abstract][Full Text] [Related]
18. The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.
Zeinalzadeh E; Valerievich Yumashev A; Rahman HS; Marofi F; Shomali N; Kafil HS; Solali S; Sajjadi-Dokht M; Vakili-Samiani S; Jarahian M; Hagh MF
Front Genet; 2021; 12():703883. PubMed ID: 34992627
[TBL] [Abstract][Full Text] [Related]
19. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
20. The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma.
Ou A; Ott M; Fang D; Heimberger AB
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
